Skip to Main Content

Author Details

Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
2004
162
32
PMIDPaper TitleJournal TitlePublished Year
37422731The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials.BJU Int2024
38035767Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.Oncologist2024
34789422Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer.Eur Urol Oncol2023
37947629The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms.Cells2023
37887551Müllerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing.Curr Oncol2023
37835368Interpreting Randomized Controlled Trials.Cancers (Basel)2023
37833193Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.Eur Urol Oncol2023
37827064Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy.Eur J Cancer2023
37573196Gender disparity trends in genitourinary oncology academic publishing over the past 3 decades: A bibliometric analysis.Urol Oncol2023
37568622A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.Cancers (Basel)2023
37725573Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes.Clin Cancer Res2023
37186844SMARCB1 regulates the hypoxic stress response in sickle cell trait.Proc Natl Acad Sci U S A2023
37286114Obesity and renal cell carcinoma: Biological mechanisms and perspectives.Semin Cancer Biol2023
37244822Renal Cell Carcinoma of Variant Histology: Biology and Therapies.Hematol Oncol Clin North Am2023
36975468Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.Curr Oncol2023
37441349Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.Eur Urol Open Sci2023
37236926SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.Nat Commun2023
37164948Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.Nat Commun2023
37226898Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.Clin Transl Med2023
36640141Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.Oncologist2023
36863962Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.Eur Urol Focus2023
36239611Less is More? First Impressions From COSMIC-313.Cancer Invest2023
36254812Risk Model Development and Validation in Clinical Oncology: Lessons Learned.Cancer Invest2023
35974457Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity.Biometrics2023
34228889Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.BJU Int2022
35442707A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.Sci Transl Med2022
35677319Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive.Ther Adv Med Oncol2022
35379845MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.Nat Commun2022
35609225Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers.Am Soc Clin Oncol Educ Book2022
35671042The Big Data Paradox in Clinical Practice.Cancer Invest2022
35697807Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.Nat Biotechnol2022
35462008Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial.Ann Oncol2022
36714159Utility-based Bayesian personalized treatment selection for advanced breast cancer.J R Stat Soc Ser C Appl Stat2022
35967405Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.Front Immunol2022
36174377The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma.Cancer Treat Res Commun2022
36010916A Causal Framework for Making Individualized Treatment Decisions in Oncology.Cancers (Basel)2022
35979929Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.Oncologist2022
36082549Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study.J Urol2022
34919008Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit.Cancer Invest2022
35241350Medicine before and after David Cox.Eur J Intern Med2022
34709109Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries.Cancer Invest2022
34561204Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics.Eur Urol Oncol2022
34362693Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.Clin Genitourin Cancer2022
32893127Causal Diagram Techniques for Urologic Oncology Research.Clin Genitourin Cancer2021
33572149Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis.Cancers (Basel)2021
33792094Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.Oncologist2021
33739450Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.Int J Cancer2021
33650321Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.Cancer Med2021
33818541The evolving treatment landscape of advanced urothelial carcinoma.Curr Opin Oncol2021
33533931Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.JAMA Netw Open2021
  • 1 - 50 of 162

Recommended Authors

Parminder Singh
Mayo Clinic
Career Start Year 2013
Number of shared co-authors 4
Irbaz Bin Riaz
Mayo Clinic
Career Start Year 2012
Number of shared co-authors 3
Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 8
Ana M Molina
Englander Institute for Precision Medicine
Career Start Year 2007
Number of shared co-authors 6
Bishoy M Faltas
Sandra and Edward Meyer Cancer Center
Career Start Year 2007
Number of shared co-authors 3
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 3
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 4
Gregory R Pond
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Career Start Year 2001
Number of shared co-authors 5
Syed A Hussain
University of Sheffield and Sheffield Teaching Hospitals
Career Start Year 2001
Number of shared co-authors 6
Jes??s Garc??a-Donas
HM Hospitales-Centro Integral Oncologico Clara Campal
Career Start Year 2001
Number of shared co-authors 2
Brian A Costello
The Mayo Clinic
Career Start Year 2001
Number of shared co-authors 5
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 2
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 1
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 5
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 5
Thomas J George
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 11
Elizabeth Garrett-Mayer
Center for Research and Analytics, American Society of Clinical Oncology
Career Start Year 1997
Number of shared co-authors 2
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 2
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 10
Nam Bui
Stanford University
Career Start Year 1996
Number of shared co-authors 3
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Career Start Year 1995
Number of shared co-authors 4
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 2
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 5
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 1
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 6
Urban Emmenegger
Odette Cancer Centre
Career Start Year 1991
Number of shared co-authors 6
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 3
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 1

Collaborators

Surena F Matin
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
Timothy P Heffernan
Co-authored papers 6
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 5
Bogdan Czerniak
University of Texas MD Anderson Cancer Center
Co-authored papers 4
Andrea Viale
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
David Goodman-Meza
David Geffen School of Medicine at University of California Los Angeles
Co-authored papers 3
Shubham Pant
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Anirban Maitra
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Wendy Kimryn Rathmell
Co-authored papers 3
Patricia J Hollen
University of Virginia School of Nursing
Co-authored papers 3
Colin P Dinney
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Charles W M Roberts
Co-authored papers 2
Elizabeth A Mullen
Co-authored papers 2
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Linghua Wang
The University of Texas M. D. Anderson
Co-authored papers 2
Najat C Daw
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Eleni Efstathiou
Houston Methodist Cancer Center
Co-authored papers 2
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 2
Franck Bourdeaut
SIREDO Oncology Center, Institut Curie Hospital, and Universite de Paris
Co-authored papers 2
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Vimal K Derebail
University of North Carolina at Chapel Hill
Co-authored papers 1
Emmanouil Fokas
Universityhospital Frankfurt
Co-authored papers 1
Yaoyi Dai
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Vinayak Bhandari
University of Toronto
Co-authored papers 1
Vince D Cataldo
Louisiana State University Health Sciences Center.
Co-authored papers 1
Sung Yun Jung
Co-authored papers 1
George Vassilakos
College of Health and Human Performance, University of Florida
Co-authored papers 1
Shawna M Hubert
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Xiao Zhao
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Jonas Demeulemeester
VIB-KU Leuven Center for Cancer Biology
Co-authored papers 1
Release 1.2